NANTES, FRANCE--(Marketwire - June 30, 2008) - VIVALIS (NYSE Euronext: VLS) announces that on 27 June 2008 it filed the BMF (Biologics Master File), for registration of the EB66® cell line with the FDA (Food and Drug Administration), the American health regulation authority. The EB66® cell line results from the EBx® technology developed by VIVALIS from duck embryonic stem cells for use in the production of vaccines and therapeutic proteins. VIVALIS has thus taken a decisive step towards regulatory approval of EBx® technology by the health authorities.
